Wallace Goldban, MD
Ophthalmology · Palm Springs, CANPI 1780872671
Payments from drug & device makers
Across 578 payments — averaging $69.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$17K
- Carl Zeiss Meditec USA, Inc.$12K
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$1K
- Alcon$1K
- Bausch & Lomb Americas Inc.$1K
- plus $6K from 24 others
What the payments were for
- Consulting fees$1500%
- Speaking & faculty fees$13,82234%
- Travel & lodging$1,9605%
- Food & beverage$12,16430%
- Education$400%
- Gifts$450%
- Other$12,15530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 45 | $16,938 |
| Carl Zeiss Meditec USA, Inc. | 11 | $12,155 |
| AbbVie(2 entities) | 69 | $1,520 |
| Sun Pharmaceutical Industries Inc. | 69 | $1,225 |
| Alcon | 50 | $1,098 |
| Bausch & Lomb Americas Inc. | 69 | $1,064 |
| Mallinckrodt Hospital Products Inc. | 54 | $951 |
| Novartis | 55 | $922 |
| Oyster Point Pharma, Inc. | 28 | $851 |
| Ivantis, Inc | 19 | $779 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 36 | $564 |
| Kala Pharmaceuticals, Inc. | 10 | $302 |
| Tarsus Pharmaceuticals, Inc. | 9 | $288 |
| Shire North American Group Inc | 6 | $227 |
| Apellis Pharmaceuticals, Inc. | 4 | $198 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $187 |
| Dompe US, Inc. | 5 | $151 |
| Harrow Eye, LLC | 6 | $134 |
| Biotissue Holdings Inc. | 4 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $116 |
| Amgen | 4 | $105 |
| Thea Pharma Inc. | 4 | $94 |
| Galderma Laboratories, L.p. | 3 | $80 |
| Eyepoint US, Inc. | 2 | $61 |
| Glaukos Corporation | 2 | $51 |
| ANI Pharmaceuticals, Inc. | 2 | $46 |
| Ocular Therapeutix, Inc. | 3 | $42 |
| Sight Sciences, Inc. | 1 | $21 |
| Tearlab Corp | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,335 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 582 | $790,814 |
| RestasisCyclosporine | 254 | $338,862 |
| Cyclosporine | 436 | $328,761 |
| CequaCyclosporine | 191 | $228,058 |
| LumiganBimatoprost | 181 | $107,854 |
| VyzultaLatanoprostene Bunod | 195 | $101,584 |
| RocklatanNetarsudil Mesylat/Latanoprost | 106 | $78,244 |
| MieboPerfluorohexyloctane/Pf | 72 | $68,005 |
| VevyeCyclosporine | 58 | $60,078 |
| RhopressaNetarsudil Mesylate | 61 | $45,202 |
| IyuzehLatanoprost/Pf | 75 | $34,128 |
| XdemvyLotilaner | 18 | $32,144 |
| TyrvayaVarenicline Tartrate | 31 | $31,301 |
| ZioptanTafluprost/Pf | 58 | $28,968 |
| TafluprostTafluprost/Pf | 102 | $24,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $1,064 | $960,403849 claims |
| AbbVieRestasis, Lumigan, Alphagan P, Restasis Multidose | $1,520 | $491,462497 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,225 | $228,058191 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $16,938 | $123,446167 claims |
| Harrow Eye, LLCVevye | $134 | $60,07858 claims |
| Thea Pharma Inc.Iyuzeh | $94 | $34,12875 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $288 | $32,14418 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $851 | $31,30131 claims |
| AlconSimbrinza | $1,098 | $7,95812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Palm Springs
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.